Pancreatic cancer is four diseases, each with new treatment possibilities
An international team led by Australian researchers has studied the genetics of pancreatic cancer, revealing it is actually four separate diseases, each with different genetic triggers and survival rates.
The research paves the way for more accurate diagnoses and treatments.
The significant findings also include 10 genetic pathways at the core of transforming normal pancreatic tissue into cancerous tumours.
Some of these processes are related to bladder and lung cancers, opening up the possibility of using treatments for these cancers to also treat pancreatic cancer.
The study was led by Professor Sean Grimmond, formerly of The University of Queensland's Institute for Molecular Bioscience (IMB), now the Director of Research & The Bertalli Chair in Cancer Medicine, University of Melbourne Centre for Cancer Research.
Published today in the international journal Nature, the research team included Professor Andrew Biankin from the Garvan Institute of Medical Research and the University of New South Wales and bioinformatician Dr Nicola Waddell, now based at QIMR Berghofer Medical Research.
Over seven years, scientists analysed the genomes of 456 pancreatic tumours to determine the core processes that are damaged when normal pancreatic tissues change into aggressive cancers.
Professor Grimmond said there was an urgent need for more knowledge about the genetic causes of pancreatic cancer, with most patients only living a few months after diagnosis and the condition predicted to become the second most common cancer in Western countries within a decade.
"We identified 32 genes from 10 genetic pathways that are consistently mutated in pancreatic tumours, but further analysis of gene activity revealed four distinct subtypes of tumours," he said.
"This study demonstrates that pancreatic cancer is better considered as four separate diseases, with different survival rates, treatments and underlying genetics.
"Knowing which subtype a patient has would allow a doctor to provide a more accurate prognosis and treatment recommendations.”
Importantly, Professor Grimmond said there are already cancer drugs, and drugs in development, that can potentially target the parts of the 'damaged machinery' driving pancreatic cancers to start.
For example some strains of pancreatic cancer are unexpectedly associated with mutations normally associated with colon cancer or leukaemia and for which experimental drugs are available or in development.
Other pancreatic cancers bear strong similarities to some bladder and lung cancers and we can start to draw on that knowledge to improve treatments," Professor Grimmond said.
In a world first, the team performed an integrated genomic analysis, meaning they combined the results of several techniques to examine not only the genetic code, but also variations in structure and gene activity, revealing more information than ever before about the genetic damage that leads to pancreatic cancer.
This study builds on earlier studies performed by the team as part of the International Cancer Genome Consortium (ICGC).
Other Australian institutions involved in the study include the University of New South Wales; St Vincent’s Hospital; University of Newcastle; Royal North Shore Hospital; University of Sydney; Royal Prince Alfred Hospital; University of Western Sydney; Fiona Stanley Hospital; Royal Adelaide Hospital; Princess Alexandra Hospital; University of Western Australia; Macarthur Cancer Therapy Centre; SA Pathology; and The University of Adelaide.
The research was funded by organisations including National Health and Medical Research Council of Australia; Queensland Government; The University of Queensland; Australian Government; Australian Cancer Research Foundation; Cancer Council NSW; Cancer Institute NSW; Garvan Institute of Medical Research; Avner Nahmani Pancreatic Cancer Research Foundation; R.T. Hall Trust; The Petre Foundation; Philip Hemstritch Foundation; and Gastroenterological Society of Australia.
Media: Bronwyn Adams, UQ Institute for Molecular Bioscience, firstname.lastname@example.org, 07 3346 2134, 0418 575 247.